{"id":"NCT00354484","sponsor":"American Regent, Inc.","briefTitle":"Safety and Efficacy of a Hematinic Agent in the Treatment of Postpartum Patients","officialTitle":"Safety and Efficacy of a Hematinic Agent in the Treatment of Postpartum Patients","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2006-05","primaryCompletion":"2006-12","completion":"2007-01","firstPosted":"2006-07-20","resultsPosted":"2013-12-05","lastUpdate":"2018-02-20"},"enrollment":291,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Postpartum Anemia"],"interventions":[{"type":"DRUG","name":"Ferric Carboxymaltose (FCM)","otherNames":[]},{"type":"DRUG","name":"Ferrous Sulfate tablets","otherNames":[]}],"arms":[{"label":"Ferric Carboxymaltose (FCM)","type":"EXPERIMENTAL"},{"label":"Ferrous Sulfate tablets","type":"ACTIVE_COMPARATOR"}],"summary":"The purpose of this study is to evaluate the efficacy, safety, and tolerability of VIT45 compared to the current standard of care in postpartum patients.","primaryOutcome":{"measure":"Number of Patients Classified as a 'Clinical Success'. Clinical Success Was Defined as the Number of Subjects With an Increase in Hemoglobin of >12 g/dL","timeFrame":"anytime between baseline and end of study or time to intervention","effectByArm":[{"arm":"Ferric Carboxymaltose (FCM)","deltaMin":127,"sd":null},{"arm":"Ferrous Sulfate Tablets","deltaMin":98,"sd":null}],"pValues":[]},"eligibility":{"minAge":null,"sex":"FEMALE","healthyVolunteers":false,"inclusionCount":4,"exclusionCount":13},"locations":{"siteCount":1,"countries":["United States"]},"refs":{"pmids":["17666600","18928998"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":4,"n":142},"commonTop":["Constipation","Headache"]}}